Kyle Landskroner International Congress on Neuronal Ceroid Lipofuscinoses 2025

Kyle Landskroner

Kyle has worked in industry for over 25 years. He is the Chief Scientific Officer for Azafaros and, since 2020, has brought a broad experience of drug development, including CMC, early-stage discovery, translational biology, pharmacokinetics, toxicology and pharmacodynamics to the Azafaros team. Previously, Kyle worked for Novartis International holding positions as Director of the Global Integration and Separation Office, Director of Portfolio Management, Global Drug Development, Portfolio Strategy and Innovation, where he was responsible for strategic reviews, clinical projects within therapeutic areas, and value-driven decision analyses for the development portfolio. From 2008 until 2012, Kyle headed In Vivo Preclinical Drug Metabolism and Pharmacokinetics at Actelion Pharmaceuticals with a focus in lysosomal storage diseases and pulmonary hypertension. Prior to Actelion, he worked for Bayer Corporation in the USA in various roles in toxicology and pharmacology. Kyle received his Ph.D. from the College of Veterinary Medicine at North Carolina State University in the USA.